Business Context and Reporting Period
This Form 8-K is a current report filed by Immudyne, Inc. (not Lifemd, Inc.) on October 23, 2017, covering events occurring on October 2, 2017. The filing discloses the appointment of a new Chief Financial Officer and the terms of his compensation agreement.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and corporate governance.
Material Changes
The primary material change reported is the appointment of Robert Kalkstein as Chief Financial Officer. The filing details a new consulting agreement with the following compensation structure:
- Monthly Fees: $2,750 (Oct-Dec 2017), $5,000 (Jan-Mar 2018), and $7,500 (Apr-Sep 2018).
- Equity Grant: An option to purchase 500,000 shares of common stock at an exercise price of $0.40 per share, subject to board approval and vesting requirements.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies are disclosed other than the standard reference to the full text of the consulting agreement filed as Exhibit 10.1. The company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the full terms and vesting schedule of the 500,000 stock options granted to the new CFO in Exhibit 10.1.
- Confirm the Board of Directors' formal approval of the stock option grant as noted in the filing.
- Review the company's capitalization table to assess the dilution impact of the new option grant.
- Check subsequent filings to confirm if the CFO appointment was permanent or if the consulting arrangement was modified.